Omnipaque products: information for supporting intrathecal risk assessment

John Minshull, Deputy Director, London Medicines Information Service, Specialist Pharmacy ServicePublished

Omnipaque products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Licensed for intrathecal use

Products licensed for intrathecal use are the first line option and should be used wherever suitable.

Omnipaque

Strength

140mg I/mL in 50mL, 75mL, 100mL, 200mL bottles
240mg I/mL in 50mL, 75mL, 100mL, 200mL bottles
300mg I/mL in 50mL, 75mL, 100mL, 200mL bottles
350mg I/mL in 50mL, 75mL, 100mL, 200mL bottles

Iohexol

Strength

300mg I/mL in 50mL,100mL vials
350mg I/mL in 50mL,100mL vials

No information available

Products with very little or no information are rarely used for intrathecal administration.

There are currently no known additional omnipaque products.

All our intrathecal product resources

Understand what to consider when giving medicines via the intrathecal route and use our material to help inform your risk assessment

Learn more about us or ask for help

Omnipaque products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
If you're a healthcare professional who needs further advice, get in touch with us. We answer questions about Medicines Optimisation issues, including those about the COVID-19 vaccination programme. Help us to help you: tell us where on our site you were.